Medford, MA, and Tucson, AZ, MedChem Partners LLC and Accendo Corporation announced today a scientific collaboration focused on the development of new chemical methods on Accendo’s Segmented Flow Reactor system. The use of flow reactor systems has been growing as it safely expands reaction conditions that enable the pursuit of new and greener chemistries. Accendo’s segmented flow reactor technology goes beyond continuous flow reactors with extreme reaction conditions (300 °C pressures of up to 150 bar), significantly reduces the amount of experimental reaction materials and dramatically increases experimental throughput. Segmented flow allows for serial-parallel operation, which increases experimental throughput by as much as 10 times that of continuous flow.

In addition, segmented flow offers the added flexibility of scalability in the same reactor system. Thus using one system a researcher can run a series of reactions at milligram scale to determine the best procedure and then switch to batch mode and prepare 100’s of grams of product using the optimized conditions. “This scientific collaboration with MedChem Partners is exciting as they will use the Propel Segmented Flow Chemistry system to develop new reaction methods while also showing the power of scalability.” says Jan Hughes, president and CEO of Accendo.

As part of the collaboration, Accendo has installed their Propel Flow Reactor System into MedChem Partners Lexington, MA facility. MedChem Partners will use the Propel to more rapidly develop new, greener chemical reaction methods using less material than traditional batch methods. “We are really looking forward to adding this capability to allow our customers access to this exciting and innovative technology” said Steven Riesinger, co-Founder of MedChem Partners.

About Us: About MedChem Partners

MedChem Partners is a medicinal chemistry service provider offering comprehensive medicinal chemistry support to biotechs, pharmaceutical companies and academic laboratories engaged in re¬search and drug discovery. The company’s expertise covers all aspects of medicinal chemistry, from strategic planning to hit evaluation and validation to lead optimization and pre-clinical development. MedChem Partners provides both consulting services as well as hands on synthesis and wet chemistry. Located just outside Boston, our modern laboratories are outfitted with all of the equip¬ment necessary to perform organic synthesis and medicinal chemistry including NMR, LC/MS and automated chromatography systems. For more information, visit us at www.MedChemPartners.com.

About Accendo Corporation

Accendo Corporation was founded in 2003 to develop automated reactor systems for organic chemistry. Engineers at Accendo have decades of experience in the development of automated life science research systems including: Peptide Synthesizers, DNA Synthesizers, Amino Acid Analyzers, Protein Sequencers, Combinatorial Reactors, Pressure Reactors, and Parallel Synthesizers. Combined, the team has developed over 20 life science instrument systems. Accendo Corporation’s charter is to develop automated reactor systems for organic and material discovery under contract as well as through the commercialization of novel reactor systems such as the Conjure™ and Propel™ Segmented Flow Chemistry Systems. For more information, visit us at www.accendocorperation.com.